GRIDX’s investment opened the door for us to take the step we were looking for: Building the AI/ML/GenAI team with the best talent available. Fortunately, I knew exactly where to start.
I called Julian Ganzabal (Juli), my companion in technological adventures for decades. Our history with AI dates back to 1994, when together we developed a version of Reversi that already incorporated heuristic and AI elements, albeit in their earliest form. This experience marked the beginning of a long journey together in the field of artificial intelligence.
In 2017, our collaboration at IAMAT led us to develop an AI system with unsupervised learning that identified clusters of “people with common interests.” Today, Juli shares his expertise at ITBA University, teaching about unsupervised learning systems, GenAI, ML, and much more.
When I invited him to join CellRep, his response was immediate. And much more – within hours he had brought on board a Biochemist with an impressive background: doctorate and postdoctoral work in immune response, experience in breast cancer research, and a specialization in Data Science and Machine Learning.
What followed was extraordinary: in just one month, we built a complete GenAI system trained on 1.5 billion molecules and uploaded databases with 400 million more. Additionally, applying methodologies similar to those we used at IAMAT, but this time cross-referencing public DNA sequencing information, we created clusters for cellular target identification.
The In Vitro team started using the system, requesting improvements like 3D molecule visualization, molecular docking analysis, and more functionalities. The results are incredible: we identified 10 molecular targets and 20 promising molecules.
The most exciting part is that in vitro tests are already confirming our hypotheses. 3 molecules are already working In Vitro! Each biological result feeds the AI models, which in turn improve our predictions, making them increasingly precise. This innovation flywheel, where biology informs AI and AI guides biological research, is what makes CellRep unique.
With each iteration, our models become more assertive in our mission: developing cellular reprogramming strategies to increase immune cell functionality. Our ultimate goal is to improve the efficiency and effectiveness of cell therapies, and with the combined power of AI and biotechnology, we’re closer than ever to achieving it.
Do you want to know more? Contact me to be part of this transformation in personalized medicine.
Alfonso Amat
